[Prevention of deep venous thrombosis in obstetrico-gynecologic surgery. Our experience with defibrotide].
Defibrotide, a new anti-thrombotic and profibrinolytic agent, has been experimented in the prophylaxis of thromboembolic disease in 99 women subjected to obstetrico-gynaecological operations. The drug's effectiveness, lack of changes in the clotting set-up and good tolerance were demonstrated. In conclusion, it is hoped that the good results obtained will promote more regular use of this drug in the prophylaxis of deep venous thrombosis in obstetrico-gynaecological surgery.
Bracciani
M
M
Zanardi
R
R
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004341:Drug Evaluation; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D005836:Genitalia, Female / Q000601:surgery*; D006801:Humans; D008875:Middle Aged; D011089:Polydeoxyribonucleotides / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000517:prevention & control*; D011247:Pregnancy; D011248:Pregnancy Complications / Q000601:surgery*; D013923:Thromboembolism / Q000473:pathology / Q000517:prevention & control*
D005343:Fibrinolytic Agents; D011089:Polydeoxyribonucleotides; C036901:defibrotide
La prevenzione delle trombosi venose profonde nella chirurgia ostetrico-ginecologica. La nostra esperienza con defibrotide.